SINGLE-DOSE THERAPY OF ANOGENITAL AND PHARYNGEAL GONORRHEA WITH CIPROFLOXACIN

被引：9

作者：

BALACHANDRAN, T ^{[1
]}

ROBERTS, AP ^{[1
]}

EVANS, BA ^{[1
]}

AZADIAN, BS ^{[1
]}

机构：

[1] CHARING CROSS HOSP,DEPT GENITOURINARY MED,FULHAM PALACE RD,LONDON W6 8RF,ENGLAND

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 1992年 / 3卷 / 01期

关键词：

CIPROFLOXACIN; RECTAL GONORRHEA; PHARYNGEAL GONORRHEA;

D O I：

10.1177/095646249200300112

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A single dose of ciprofloxacin, 250 mg by mouth, was used in an open study to treat pharyngeal or rectal gonorrhoea or both in 64 patients (32 men and 32 women). The study also included 151 men with urethral gonorrhoea and 53 women with cervical or urethral gonorrhoea. Ciprofloxacin cured 63 (98%) patients with pharyngeal or rectal gonorrhoea (including 5 patients with penicillinase-producing Neisseria gonorrhoeae; PPNG), 147 (97%) men with urethral gonorrhoea (including 8 with PPNG) and 52 (98%) women with cervical or urethral gonorrhoea. All the isolates of N. gonorrhoeae were sensitive to 0.03 mg/l of ciprofloxacin. Five of the 6 patients with treatment failure were subsequently cured by a single oral dose of ciprofloxacin 250 mg. None of the patients reported an adverse reaction. Ciprofloxacin 250 mg as a single oral dose is effective and safe in treating patients with pharyngeal or rectal gonorrhoea, including those with PPNG strains.

引用

页码：49 / 51

页数：3